Opinion|Videos|July 10, 2024
EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
- Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?
Advertisement
Related to this article
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5